Clinical Trial Update: Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating Pylarify (piflufolastat F-18) PET/CT for suspected or high-risk metastatic clear cell renal cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Pylarify (piflufolastat F-18)

Snippet

Sponsor: Lantheus Medical Imaging | Conditions: Clear Cell Renal Cell Carcinoma | Phase 2, Phase 3 | Status: WITHDRAWN